Positivity for BAFF-R and CXCR5 was decreased in the total B cell population from CIS/MS patients (Figure 4A) and expression levels (mfi) of BAFF-R were also decreased across B cells that were BAFF-R+ (Figure 4B). This evidence concerns the gene CXCR5 and in situ carcinoma.